Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.47 |
| ▸ | MAOB | P27338 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814842 | 0.88 | CHRNA7 (0.56) | MAOAMAOBCHRNA7 | |
| SCHEMBL3970008 | 0.88 | CHRNA7 (0.56) | MAOAMAOBCHRNA7 | |
| SCHEMBL4813423 | 0.86 | CHEK1 (0.48) | ALDH1A1 | |
| SCHEMBL9620526 | 0.83 | MAOA (0.57) | MAOAMAOBCHRNA7 | |
| SCHEMBL9621181 | 0.83 | MAOA (0.57) | MAOAMAOBCHRNA7 | |
| SCHEMBL27895 | 0.82 | MAOB (0.67) | MAOAMAOB | |
| SCHEMBL4708272 | 0.82 | MAOB (0.67) | MAOAMAOB | |
| SCHEMBL5713217 | 0.81 | MAOA (0.61) | MAOAMAOBCHRNA7 | |
| SCHEMBL11147426 | 0.81 | MAOA (0.61) | MAOAMAOBCHRNA7 | |
| SCHEMBL4192600 | 0.80 | MAOB (0.56) | MAOAMAOBALDH1A1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | MAOA 3621/4885MAOB 3311/4885ALDH1A1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.